MARKET

BIIB

BIIB

Biogen Inc
NASDAQ
187.57
+3.73
+2.03%
After Hours: 187.00 -0.57 -0.30% 18:23 03/30 EDT
OPEN
186.16
PREV CLOSE
183.84
HIGH
190.09
LOW
185.51
VOLUME
799.93K
TURNOVER
--
52 WEEK HIGH
202.41
52 WEEK LOW
110.04
MARKET CAP
27.53B
P/E (TTM)
21.34
1D
5D
1M
3M
1Y
5Y
1D
Mixed Action for Stocks as Treasury Yields Retreat on Jerome Powell Commentary
NASDAQ · 12h ago
Biogen Stock Pops After FDA Approves New High-Dose Spinraza For Spinal Muscular Atrophy
Benzinga · 13h ago
Biogen receives FDA approval for high-dose Spinraza regimen
Seeking Alpha · 14h ago
BUZZ-U.S. STOCKS ON THE MOVE-Agnico Eagle Mines, ProPetro, Kezar
Reuters · 14h ago
BIOGEN WILL INTRODUCE 28 MG VIAL AT SAME PRICE AS 12 MG VIAL, RESULTING IN PARITY PRICING FOR PATIENTS IN THE MAINTENANCE PHASE- SPOKESPERSON
Reuters · 16h ago
BIOGEN: WAC OF SPINRAZA 12 MG & 28 MG VIALS IS THE SAME AT ABOUT $152,000, WAC OF 50 MG VIAL IS ABOUT $271,000 - SPOKESPERSON
Reuters · 16h ago
BIOGEN: DO NOT EXPECT ANY ADDITIONAL OUT-OF-POCKET COSTS FOR MAJORITY OF EXISTING SPINRAZA PATIENTS - SPOKESPERSON
Reuters · 16h ago
High-dose Spinraza approval, AMETHYST data drivers for Biogen, says BMO Capital
TipRanks · 17h ago
More
About BIIB
Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).

Webull offers Biogen Inc stock information, including NASDAQ: BIIB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BIIB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BIIB stock methods without spending real money on the virtual paper trading platform.